-
公开(公告)号：EP4403574A1
公开(公告)日：2024-07-24
申请号：EP22869313.1
申请日：2022-09-15
发明人： CAO, Zhiliang , WANG, Baohui , LIN, Yuan , LIN, Kan , LIAO, Cheng
IPC分类号： C07K16/28 , C12N15/13 , A61K39/395 , A61P35/00
CPC分类号： C07K16/00 , A61K39/395 , C07K16/28 , A61P35/00
摘要： The present disclosure relates to a protein specifically binding to PD-1 and a pharmaceutical use thereof. Specifically, the present disclosure provides a protein specifically binding to PD-1, a protein specifically binding to PD-1/PVRIG/TIGIT, and a use thereof in the treatment of a disease (such as cancer).
-
公开(公告)号：EP4393950A1
公开(公告)日：2024-07-03
申请号：EP22860540.8
申请日：2022-08-24
发明人： LIN, Yuan , CHEN, Simeng , WU, Tingting , HU, Rongting , LIAO, Cheng
摘要： An FAP/CD40 binding molecule and the medicinal use thereof. Specifically, provided are an FAP binding molecule, a CD40 binding molecule and an FAP/CD40 binding molecule, a method for preventing and treating diseases (such as tumors or cancers) using same, and the medicinal use thereof.
-
公开(公告)号：EP4365200A1
公开(公告)日：2024-05-08
申请号：EP22832015.6
申请日：2022-06-28
发明人： LIN, Yuan , SU, Lu , LIN, Kan , LIAO, Cheng
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： A61K39/395 , C07K16/28
摘要： Provided are an anti-CD40 antibody, an antigen-binding fragment and a medical use thereof, as well as a pharmaceutical composition containing the anti-CD40 antibody or antigen-binding fragment thereof, and a method for treating and preventing disease, in particular a method for treating autoimmune disease.
-
公开(公告)号：EP4119162A1
公开(公告)日：2023-01-18
申请号：EP21768888.6
申请日：2021-03-12
发明人： LIN, Yuan , LIN, Kan , JIN, Xinsheng , ZHANG, Man , LIAO, Cheng
IPC分类号： A61K39/395 , A61P35/00 , C07K16/28 , C07K7/06 , C12N15/13 , G01N33/574
摘要： A PVRIG binding protein and its medical uses. Specifically, an anti-PVRIG single-domain antibody and an anti-PVRIG and -TIGIT bispecific antibody, pharmaceutical compositions comprising the antibodies, a method for treating cancer, and pharmaceutical uses.
-
5.发明公开
公开(公告)号：EP4269447A1
公开(公告)日：2023-11-01
申请号：EP21909437.2
申请日：2021-12-22
发明人： WANG, Huan , LIN, Yuan , TANG, Yucheng , KE, Ke , LIN, Kan , LIAO, Cheng
摘要： Provided are a complex of an anti-IL-4R antibody or an antigen-binding fragment thereof, and a medical use thereof. Specifically, provided are a complex of an antibody that specifically binds to IL-4R or an antigen-binding fragment thereof covalently linked to a toxin, a pharmaceutical composition comprising the complex, and a use thereof in the preparation of a drug for treating IL-4R-mediated diseases or disorders, especially a use in the preparation of an anti-cancer drug.
-
公开(公告)号：EP4108683A1
公开(公告)日：2022-12-28
申请号：EP21756707.2
申请日：2021-02-19
发明人： LIN, Yuan , ZHU, Fuxiang , LIAO, Cheng
IPC分类号： C07K16/24 , A61K39/395 , A61K39/00
摘要： Provided are an anti-IL-2 antibody, and an antigen-binding fragment thereof and the medical use thereof. Further provided are a complex (including a fusion protein) of the anti-IL-2 antibody, the antigen-binding fragment thereof and IL-2, and the use of the complex as a drug for treating autoimmune diseases and inflammatory diseases.
-
公开(公告)号：EP3875475A1
公开(公告)日：2021-09-08
申请号：EP19898340.5
申请日：2019-12-20
申请人： Jiangsu Hengrui Medicine Co., Ltd. , Shanghai Hengrui Pharmaceutical Co., Ltd. , Shanghai Shengdi Pharmaceutical Co., Ltd
发明人： CHEN, Lei , HU, Qiyue , GE, Hu , LIN, Yuan , WANG, Hongwei , OU, Yangchao , KONG, Xianglin , LIAO, Cheng , ZHANG, Lianshan
IPC分类号： C07K14/55 , C07K17/08 , C07K19/00 , C12N15/26 , C12N15/63 , C12P21/02 , A61K38/20 , A61K47/60 , A61K47/62 , A61K47/68 , A61P35/00 , A61P37/00
摘要： Provided is a human interleukin-2 (IL-2) variant having one or more amino acid mutations or a derivative thereof. The IL-2 variant or derivative thereof has increased stability compared to wild-type IL-2 and improved properties as an immunotherapeutic agent. Also disclosed are an immunoconjugate and a pharmaceutical composition which comprise the human IL-2 variant or derivative thereof, a polynucleotide molecule encoding same, a vector, a host cell and a preparation method therefor, as well as the pharmaceutical uses of the IL-2 variant or derivative thereof and the immunoconjugate or pharmaceutical composition comprising the L-2 variant or derivative thereof.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.016 秒)
